Includes Oral Presentation on CD123-Targeting ADC IMGN632
IMGN632, a CD123-targeting ADC and IMGN779, a CD33-targeting ADC, both use ImmunoGen's new family of indolino-benzodiazepine cancer-killing agents called IGNs. ImmunoGen designed IGN payloads to alkylate DNA without crosslinking it. Data being presented at ASH will demonstrate that DNA-alkylating IGNs are ultra-potent, yet provide increased tolerability compared with DNA crosslinking versions.
"Accelerating our earlier-stage portfolio with an emphasis on our IGN
ADCs is one of ImmunoGen's strategic priorities, and we believe the
IMGN632 and IMGN779 preclinical data being presented at ASH further
demonstrate why we are excited about the potential of these programs,"
In an oral presentation, the Company will report preclinical data demonstrating the activity of IMGN632 in multiple acute myeloid leukemia (AML) models and patient samples at concentrations far below levels that affect normal bone marrow cells, suggesting the potential for efficacy in AML patients in the absence of or with limited myelosuppression. In a separate poster presentation, preclinical data for IMGN632 will be reported demonstrating prolonged survival in AML xenograft models. Preclinical data from a combination study of IMGN779 with a PARP inhibitor, demonstrating enhanced activity in several AML models including patient derived tumor cells and a disseminated AML xenograft model, will also be presented in an investigator poster presentation.
A Phase 1 trial of IMGN779 as monotherapy in AML is ongoing with the first clinical data expected to be reported in 2017. ImmunoGen intends to submit an IND application and initiate clinical testing of IMGN632 in 2017.
Title: "A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells"
Title: "IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models"
Title: "Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models"
Data will also be presented on agents which use ImmunoGen's maytansinoid ADC technology, including IMGN529 and Biotest's indatuximab ravtansine (BT062).
Additional information, including abstracts, can be found at www.hematology.org.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including IMGN632 and IMGN779, including risks related to preclinical
and clinical studies, their timings and results. A review of these risks
can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
News Provided by Acquire Media